Biocon Share Price (BIOCON)
Check the latest share price of Biocon, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Biocon Stock Performance
Get live Biocon share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹345Day's Price Range₹357.952 Week's Low
52 Week's High
₹29152-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | + 5.09 % |
| 3 Month Return | + 6.65 % |
| 1 Year Return | + 6.15 % |
| 3 Year Return | + 8.87 % |
| 5 Year Return | -8.3 % |
| Market Stats | |
| Previous Close | ₹352.25 |
| Open | ₹347.95 |
| Volume | 80.14L |
| Upper Circuit | ₹387.45 |
| Lower Circuit | ₹317.05 |
Biocon Fundamentals & Key Indicators
Check Biocon market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹42,669.32 Cr
Return on Equity (ROE)
0.97
PE Ratio (TTM)
41.96
Return on capital employed (ROCE)
2.61
Industry PE ratio
57.39
Beta (LTM)
1.2
P/B Ratio
2.91
Dividend Yield
0.19
PEG Ratio
-524.5
Quarterly Earnings Growth YOY
106.1
EPS (TTM)
10.81
Sector
Pharmaceuticals
Book Value
164.77
Technical Analysis
Bullish
View Technical Analysis
How to invest in Biocon?
Investing in Biocon is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Biocon or BIOCON on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Biocon or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Biocon with just a few clicks!
Biocon Stock's Interest Amongst Investors
Biocon Valuation
Track how Biocon P/E has moved over time to understand its valuation trends.
Biocon in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (41.96x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (118.86x)
September 27, 2018
Today’s Price to Earnings Ratio: 41.96x
Biocon Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Biocon.
based on 21 analysts
60.00%
Buy
15.00%
Hold
25.00%
Sell
60% of analysts recommend a 'BUY' rating for Biocon. Average target price of ₹377.86
Source: S&P Global Market Intelligence
Biocon Share Price Target
Get share price movements and forecasts by analysts on Biocon.
Biocon price forecast by 21 analysts
Upside of6.32%
High
₹447
Target
₹377.86
Low
₹270
Biocon target price ₹377.86, a slight upside of 6.32% compared to current price of ₹355.4. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2027:40.05%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2027:40.96%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Financial Results
Get the annual and quarterly financial summary of Biocon, including revenue, profit, loss and more.
Indices Featuring Biocon Stock
Check stock indices that include Biocon.
Biocon Earnings and Dividends
View detailed summary of the earnings and dividend history of Biocon.
Biocon Ltd Earnings Results
Biocon Ltd’s net profit jumped 154.24% since last year same period to ₹344.50Cr in the Q4 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 1272.51% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.56%.
Read More about Dividends
Biocon Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Biocon.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.66% | 0.00 | |
| Mutual Funds | 8.77% | 0.00 | |
| Retail Investors | 17.76% | 0.00 | |
| Others | 7.17% | 0.00 |
Biocon vs Peers
Compare market cap, revenue, PE, and other key metrics of Biocon with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 42,669.32 | -1.66% | 0.58 | 1,297 | 14,755 | |
| HOLD | 1,76,987.90 | 37.1% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,10,074.44 | 32.82% | 0.67 | 1,656 | 10,727 | |
| HOLD | 27,838.89 | -1.43% | 0.50 | 772 | 5,664 | |
| BUY | 1,21,573.55 | 26.77% | 0.50 | 4,155 | 25,774 |
Biocon News & Key Events
Latest news and events in one place to help you make informed investing decisions in Biocon.
Biocon Ltd Gains for Third Straight Session - 11 Jun, 2025
Biocon Ltd's stock rose 3.52% to Rs 353.2, marking its third consecutive gain. The stock has increased 4.22% over the past year, outperforming NIFTY and Nifty Pharma index gains. Monthly gains stand at 7.63%, with trading volume significantly above average.Biocon Launches BioWISE Program for Women in STEM - 09 Jun, 2025
Biocon Foundation, in collaboration with NCBS and BeST Cluster, has launched the BioWISE initiative to support 25 women science students in Karnataka through scholarships and mentorship.Biocon Doubles Insulin Capacity, Sees Growth Ahead - 06 Jun, 2025
Biocon has doubled its insulin manufacturing capacity in Malaysia, positioning itself as a key player in the market. Chairperson Kiran Mazumdar-Shaw anticipates significant growth in FY26, driven by rising global demand for insulin.Biocon Advances Diabetes Treatment with Key Approvals - 02 Jun, 2025
Biocon secures CDSCO approval for Liraglutide, a significant diabetes treatment. CEO Kiran Mazumdar Shaw emphasizes Biocon's strategy to dominate the diabesity market and expand its GLP-1 pipeline.Biocon Biologics Receives UK Approval for YESINTEK® - 25 May, 2025
Biocon Biologics Ltd has received marketing authorization from the UK's MHRA for YESINTEK®, a biosimilar for Ustekinumab, approved for treating psoriasis and other conditions. This follows recent EU approval, enhancing access to biosimilars.Biocon Secures Extension for Malaysian Insulin Supply - 22 May, 2025
Biocon Biologics has received a six-month extension for its insulin supply contract with the Malaysian government, now valid until October 28, 2025. This extension reinforces Biocon's commitment to providing affordable insulin access in Malaysia and globally.Biocon Launches Ustekinumab Biosimilar in Japan - 21 May, 2025
Biocon Biologics successfully launched its Ustekinumab BS Subcutaneous Injection in Japan, leading to a 2% rise in Biocon shares. The biosimilar targets psoriasis and psoriatic arthritis, expanding Biocon's market presence after previous launches in the US and Europe. Strong quarterly results further support investor confidence.Biocon Ltd Continues Upward Trend for Fifth Session - 19 May, 2025
Biocon Ltd shares rose 1.3% today, marking the fifth consecutive session of gains. The stock is currently priced at Rs 343.8, up 11.77% over the past year, outperforming the NIFTY and Nifty Pharma indices. Volume is lower than average, with 7.5 lakh shares traded today.Biocon Pharma Secures FDA Approval for Rivaroxaban - 16 May, 2025
Biocon's subsidiary, Biocon Pharma, has received US FDA approval for Rivaroxaban Tablets, strengthening its portfolio. The company reported a 154.24% profit surge in Q4 FY25.Biocon's Growth Prospects and Fundraising Plans Highlighted - 15 May, 2025
Biocon is set to raise ₹4,500 crore through a QIP to enhance its stake in Biocon Biologics. Investec has initiated a 'buy' rating, emphasizing growth in biosimilars. CEO Siddharth Mittal noted strong momentum across business segments and opportunities in the GLP market.Biocon Evaluates Merger, Stock Shows Positive Movement - 14 May, 2025
Biocon is exploring a merger of its biosimilars unit while postponing IPO plans due to market volatility. Despite this, shares rose 2.11%. ICICI Securities maintains a Sell rating with a revised target price of Rs 270, citing margin concerns.Biocon Projects Mid-Teens Revenue Growth - 13 May, 2025
Biocon's leadership projects mid-teens revenue growth for FY26, driven by strong performance in biosimilars and generics. Citigroup maintains a buy rating despite recent challenges.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 8.58% to 8.77% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -16.0 Cr → 344.5 Cr (in ₹), with an average increase of 128.2% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 3.64K Cr → 4.47K Cr (in ₹), with an average increase of 9.6% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, BIOCON stock has moved up by 5.1%
NO EFFECTAgainst Peers
In the last 1 year, Vimta Labs Ltd has given 104.5% return, outperforming this stock by 98.4%
- NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 5.66% of holdings in Mar 2025 quarter
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Vimta Labs Ltd has given 223.6% return, outperforming this stock by 214.7%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.12% to 17.76% in Mar 2025 quarter
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹4,358.10Cr as on March 2025 (Q4 FY25)
Net Profit: ₹459.40Cr as on March 2025 (Q4 FY25)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon Ltd |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| CEO | Kiran Mazumdar Shaw |
| E-voting on shares | Click here to vote |
Mutual Funds that own Biocon
Check out the Mutual Funds with significant holdings in Biocon.
FAQs
What is Biocon share price today?
Biocon share price today stands at ₹355.4, Open: ₹347.95, Previous Close: ₹352.25, High: ₹357.9, Low: ₹345, 52 Week High: ₹404.7, 52 Week Low: ₹291.
What is today's traded volume of Biocon?
Today's traded volume of Biocon is 80.14L. Which means that 80.14L shares of Biocon were bought and sold on the stock market during today's trading session.
What is Biocon's market cap today?
Today's market capitalisation of Biocon is ₹42,669.32 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Biocon?
Biocon’s 52 week high is ₹404.7 and 52 week low is ₹291. The current share price of Biocon is ₹355.4, which is -12.18% down from its 52 week high and 22.13% up from its 52 week low.